Stifel Reiterates Buy Rating on Biogen (BIIB) Following Acquisition of HI-Bio
Tweet Send to a Friend
Stifel analyst Paul Matteis reiterated a Buy rating and $275.00 price target on Biogen (NASDAQ: BIIB).The analyst comments "BIIB announced ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
